In this article, we will discuss Lenvatinib (Dosage Overview). So, let’s get started.
Differentiated Thyroid Cancer
Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
Renal Cell Carcinoma
Lenvatinib is indicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy.
Lenvatinib is indicated for the first-line treatment of patients with unresectable
hepatocellular carcinoma (HCC).
Important Dosage Information
Reduce the dose for certain patients with renal or hepatic impairment.
Take Lenvatinib once daily, with or without food, at the same time each day. If a dose is missed and cannot be taken within 12 hours, skip that dose and take the next dose at the usual time of administration.
Recommended Dosage for Differentiated Thyroid Cancer (DTC)
The recommended dosage of Lenvatinib is 24 mg orally once daily until disease progression or until unacceptable toxicity.
Recommended Dosage for Renal Cell Carcinoma (RCC)
The recommended dosage of Lenvatinib is 18 mg in combination with 5 mg everolimus
orally once daily until disease progression or until unacceptable toxicity. Refer to everolimus prescribing information for recommended everolimus dosing information.
Recommended Dosage for Hepatocellular Carcinoma (HCC)
The recommended dosage of Lenvatinib is based on actual body weight:
12 mg for patients greater than or equal to 60 kg or 8 mg for patients less than 60 kg.
Take Lenvatinib orally once daily until disease progression or until unacceptable toxicity.